Tag: metastasis

‘Dawn of a New Era’ in the Treatment of Renal Cell Carcinoma

The decades-long search for a safe, effective adjuvant therapy for patients with resected kidney cancer at high risk of recurrence appears to have taken a...

Kathy O’Brien, Critic of Cancer Bell Ringing, Dies at 56

Katherine O’Brien, who lived with metastatic breast cancer for 12 years and left her mark on American cancer care, died June 19 after a rapid...

No Benefit in Cervical Cancer With Adjuvant Chemo

One of the top presentations at the top cancer meeting this year has negative results — but this abstract is “very important,” says Lori J....

Olaparib in BRCA+ Breast Cancer

New clinical data show that the PARP inhibitor olaparib (Lynparza, AstraZeneca/Merck) also has a place in the treatment of early stage breast cancer with BRCA...

Neoadjuvant Systemic Therapy Promising for Resectable Colorectal Peritoneal Metastases

NEW YORK (Reuters Health) – Perioperative systemic therapy seemed feasible, safe and capable of inducing a response in a phase 2 trial comparing the treatment...

FDA Panel Votes Against Two Cancer Indications but Backs 4 of 6

Federal advisers this week supported the efforts of pharmaceutical companies in 4 of 6 cases in which these firms are fighting to maintain cancer indications...

Veterinarian Helps Perform ‘Unproven’ Human Surgery

Millions Paid to Resolve Multiple Claims Involving “Unproven” Knee Surgery In what’s believed to be one of the largest public payouts in recent years, the...

No Survival Benefit to Primary Resection Before Chemo in CRC

NEW YORK (Reuters Health) – Contrary to previous reports, primary tumor resection prior to chemotherapy did not confer a survival benefit in colorectal cancer patients...

FDA Approves Cemiplimab-rwlc for NSCLC With PD-L1 Expression

The US Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for the treatment of advanced non–small cell lung cancer (NSCLC). Specifically, the indication is...

CCR Score Can Guide Treatment After Radiation in Prostate Cancer

The combined clinical cell-cycle risk (CCR) score — derived from both clinical and genetic factors — can identify patients with intermediate- and high-risk localized prostate...

Liquid vs Tissue Biopsy in Prostate Cancer: Why Not Both?

The genomic landscape of circulating tumor DNA (ctDNA) was comparable to the landscape of tissue biopsies in a large study of patients with metastatic castration-resistant...

Liquid Biopsies Helpful in Prostate Cancer, but Most Not Ready for Routine Use

NEW YORK (Reuters Health) – Liquid biopsies have the potential to guide therapeutic decision making in prostate cancer, but issues such as assay standardization, cost...

Obesity ‘Clearly’ Not Tied to Worse Survival in MBC

The relationship between obesity and overweight and breast cancer has some elements of mystery. But this is not one of them: in metastatic breast cancer...

Entinostat Doesn’t Overcome Endocrine Resistance in Breast Cancer

The histone deacetylase (HDAC) inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor–positive, HER2-negative, advanced breast cancer in a phase 3 trial....

After 48 Years, NCI Aims to Track Breast Cancer Recurrences

  Patients with breast cancer want accurate information on the risk of their cancer recurring once they have completed treatment. “I would like to know...

Palbociclib Disappoints in HR+, HER2– Breast Cancer

The CDK4/6 inhibitor palbociclib provides no significant benefit in patients with hormone receptor–positive (HR+), HER2-negative primary breast cancer, according to first results from the PENELOPE-B...

Beta-Blocker May Improve Melanoma Treatment Response

Response rates were high without dose-limiting toxicities in a small phase 1 study that evaluated the addition of propranolol to pembrolizumab in treatment-naive patients with...

Pembrolizumab ‘Preferred Choice’ in MSI-H/dMMR Metastatic CRC

Frontline pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) compared with chemotherapy among patients with microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer, according to results from...

FDA Approves First Agent for PSMA-PET Imaging in Prostate Cancer

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68...

Mitotic Rate Makes Comeback as Melanoma Prognosticator

Mitotic rate, properly applied, has a prognostic impact in melanoma comparable to that of lesional ulceration, Mohammed Kashani-Sabet, MD, reported at a virtual forum on...

SRS Instead of WBRT for Patients With Multiple Brain Metastases

Stereotactic radiosurgery (SRS) should replace whole-brain radiotherapy (WBRT) as the new standard of care for patients with four or more brain metastases, say researchers who...

Performance Status, Molecular Testing Key to Cancer Prognosis

Performance status and molecular testing results are key tools in prognosticating for patients with newly diagnosed metastatic solid tumors, according to Sam Brondfield, MD, MA,...

Chronicles of Cancer: A History of Mammography

The history of mammography provides a powerful example of the connection between social factors and the rise of a medical technology. It is also an...

Adjuvant Systemic Chemotherapy Tied to Better Survival After Resection of Colorectal Peritoneal Metastases

NEW YORK (Reuters Health) – Adjuvant systemic chemotherapy following resection of isolated synchronous colorectal peritoneal metastases is associated with improved survival compared with active surveillance,...

Genetic Differences by Ancestry and Prostate Cancer Therapies

There are genetic differences when comparing prostate tumors from African American men and European-American men, but none of these differences are of clinical significance for...